SMART Health Cards: Vaccination & Testing Implementation Guide, published by HL7 International / Public Health. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-shc-vaccination-ig/ and changes regularly. See the Directory of published versions
Official URL: http://hl7.org/fhir/uv/shc-vaccination/ValueSet/immunization-all-cvx | Version: 1.0.0 | |||
Standards status: Trial-use | Maturity Level: 4 | Computable Name: ImmunizationAllCvxValueSet |
Contains all CVX codes from https://www2.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx as of 2025-09-03. This list of codes will not update automatically, so please refer to this URL for the most up-to-date codes.the most up-to-date codes.
References
http://hl7.org/fhir/sid/cvx
Code | Display |
54 | adenovirus, type 4 |
55 | adenovirus, type 7 |
82 | adenovirus, unspecified formulation |
24 | Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis |
19 | BCG |
27 | botulinum antitoxin |
26 | cholera, unspecified formulation |
29 | CMVIG |
56 | dengue fever tetravalent |
12 | diphtheria antitoxin |
28 | DT (pediatric) |
20 | DTaP |
106 | DTaP, 5 pertussis antigens |
107 | DTaP, unspecified formulation |
110 | DTaP-Hep B-IPV |
50 | DTaP-Hib |
120 | DTaP-Hib-IPV |
130 | DTaP-IPV |
22 | DTP-Hib |
102 | DTP-Hib-Hep B |
57 | hantavirus |
52 | Hep A, adult |
83 | Hep A, ped/adol, 2 dose |
84 | Hep A, ped/adol, 3 dose |
31 | Hep A, pediatric, unspecified formulation |
85 | Hep A, unspecified formulation |
104 | Hep A-Hep B |
30 | HBIG |
42 | Hep B, adolescent/high risk infant |
43 | Hep B, adult |
44 | Hep B, high-dosage, dialysis or IC |
45 | Hep B, unspecified formulation |
58 | Hep C |
59 | Hep E |
60 | herpes simplex 2 |
46 | Hib (PRP-D) |
47 | Hib (HbOC) |
48 | Hib (PRP-T) |
49 | Hib (PRP-OMP) |
17 | Hib, unspecified formulation |
51 | Hib-Hep B |
61 | HIV |
118 | HPV, bivalent |
62 | HPV, quadrivalent |
86 | IG |
87 | IGIV |
14 | IG, unspecified formulation |
111 | Influenza, live, trivalent, intranasal, PF |
15 | influenza, split (incl. purified surface antigen) |
16 | influenza, whole |
88 | influenza, unspecified formulation |
123 | influenza, H5N1-1203 |
10 | IPV |
89 | polio, unspecified formulation |
39 | Japanese encephalitis SC |
63 | Junin virus |
64 | leishmaniasis |
65 | leprosy |
66 | Lyme disease |
94 | MMRV |
67 | malaria |
68 | melanoma |
32 | meningococcal MPSV4 |
103 | meningococcal C conjugate |
114 | meningococcal MCV4P |
108 | meningococcal ACWY, unspecified formulation |
69 | parainfluenza-3 |
11 | pertussis |
23 | plague |
33 | pneumococcal polysaccharide PPV23 |
100 | pneumococcal conjugate PCV 7 |
109 | pneumococcal, unspecified formulation |
70 | Q fever |
18 | rabies, intramuscular injection |
40 | rabies, intradermal injection |
90 | rabies, unspecified formulation |
72 | rheumatic fever |
73 | Rift Valley fever |
34 | RIG |
119 | rotavirus, monovalent |
122 | rotavirus, unspecified formulation |
116 | rotavirus, pentavalent |
74 | rotavirus, tetravalent |
71 | RSV-IGIV |
93 | RSV-MAb |
38 | rubella/mumps |
76 | Staphylococcus bacterio lysate |
113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed |
115 | Tdap |
35 | tetanus toxoid, adsorbed |
112 | tetanus toxoid, unspecified formulation |
77 | Tick-borne encephalitis vaccine (non-US) |
13 | TIG |
95 | TST-OT tine test |
96 | TST-PPD intradermal |
97 | TST-PPD tine test |
98 | TST, unspecified formulation |
78 | tularemia vaccine |
91 | typhoid, unspecified formulation |
25 | typhoid, oral |
41 | typhoid, parenteral |
53 | typhoid, parenteral, AKD (U.S. military) |
101 | typhoid, ViCPs |
75 | Vaccinia (smallpox, mpox), live |
105 | vaccinia (smallpox) diluted |
79 | vaccinia immune globulin |
21 | varicella |
81 | VEE, inactivated |
80 | VEE, live |
92 | VEE, unspecified formulation |
36 | VZIG |
117 | VZIG (IND) |
37 | yellow fever live |
121 | zoster live |
998 | no vaccine administered |
999 | unknown |
99 | RESERVED - do not use |
133 | Pneumococcal conjugate PCV 13 |
134 | Japanese Encephalitis IM |
137 | HPV, unspecified formulation |
136 | Meningococcal MCV4O |
135 | Influenza, high-dose, trivalent, PF |
131 | typhus, historical |
132 | DTaP-IPV-HIB-HEP B, historical |
128 | Novel Influenza-H1N1-09, all formulations |
125 | Novel Influenza-H1N1-09, nasal |
126 | Novel influenza-H1N1-09, preservative-free |
127 | Novel influenza-H1N1-09 |
138 | Td (adult) |
139 | Td(adult) unspecified formulation |
140 | Influenza, split virus, trivalent, PF |
129 | Japanese Encephalitis, unspecified formulation |
141 | Influenza, split virus, trivalent, preservative |
142 | tetanus toxoid, not adsorbed |
143 | Adenovirus types 4 and 7 |
144 | influenza, seasonal, intradermal, preservative free |
145 | RSV-MAb (new) |
146 | DTaP,IPV,Hib,HepB |
147 | meningococcal MCV4, unspecified formulation |
148 | Meningococcal C/Y-HIB PRP |
149 | Influenza, live, quadrivalent, intranasal |
150 | Influenza, split virus, quadrivalent, PF |
151 | influenza nasal, unspecified formulation |
152 | Pneumococcal Conjugate, unspecified formulation |
153 | Influenza, MDCK, trivalent, PF |
154 | Hep A, IG |
155 | Influenza, recombinant, trivalent, PF |
156 | Rho(D)-IG |
157 | Rho(D) -IG IM |
158 | Influenza, split virus, quadrivalent, preservative |
159 | Rho(D) - Unspecified formulation |
160 | Influenza A monovalent (H5N1), ADJUVANTED-2013 |
801 | AS03 Adjuvant |
161 | Influenza, injectable,quadrivalent, preservative free, pediatric |
162 | meningococcal B, recombinant |
163 | meningococcal B, OMV |
164 | meningococcal B, unspecified |
165 | HPV9 |
166 | influenza, intradermal, quadrivalent, preservative free |
167 | meningococcal, unknown serogroups |
168 | Influenza, adjuvanted, trivalent, PF |
169 | Hep A, live attenuated |
170 | DTAP/IPV/HIB - non-US |
171 | Influenza, MDCK, quadrivalent, PF |
172 | cholera, WC-rBS |
173 | cholera, BivWC |
174 | cholera, live attenuated |
175 | Rabies - IM Diploid cell culture |
176 | Rabies - IM fibroblast culture |
177 | PCV10 |
178 | OPV bivalent |
179 | OPV ,monovalent, unspecified |
180 | tetanus immune globulin |
181 | anthrax immune globulin |
182 | OPV, Unspecified |
183 | Yellow fever vaccine live - alt |
184 | Yellow fever, unspecified |
185 | Influenza, recombinant, quadrivalent, PF |
186 | Influenza, MDCK, quadrivalent, preservative |
187 | zoster recombinant |
188 | zoster, unspecified formulation |
189 | HepB-CpG |
190 | Typhoid conjugate vaccine (TCV) |
191 | meningococcal A polysaccharide (non-US) |
192 | meningococcal AC polysaccharide (non-US) |
193 | Hep A-Hep B, pediatric/adolescent |
194 | Influenza, Southern Hemisphere |
195 | DT, IPV adsorbed |
196 | Td, adsorbed, preservative free, adult use, Lf unspecified |
197 | Influenza, high-dose, quadrivalent, PF |
200 | influenza, Southern Hemisphere, pediatric, preservative free |
201 | Influenza, Southern Hemisphere, quadrivalent, PF |
202 | influenza, Southern Hemisphere, quadrivalent, with preservative |
198 | DTP-hepB-Hib Pentavalent Non-US |
203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) |
205 | Influenza, adjuvanted, quadrivalent, PF |
206 | Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection |
207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose |
208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose |
213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED |
210 | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL |
212 | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL |
204 | Ebola Zaire vaccine, live, recombinant, 1mL dose |
214 | Ebola, unspecified |
211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL |
500 | COVID-19 Non-US Vaccine, Product Unknown |
501 | COVID-19 IV Non-US Vaccine (QAZCOVID-IN) |
502 | COVID-19 IV Non-US Vaccine (COVAXIN) |
503 | COVID-19 LAV Non-US Vaccine (COVIVAC) |
504 | COVID-19 VVnr Non-US Vaccine (Sputnik Light) |
505 | COVID-19 VVnr Non-US Vaccine (Sputnik V) |
506 | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology |
507 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences) |
508 | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) |
509 | COVID-19 PS Non-US Vaccine (EpiVacCorona) |
510 | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) |
511 | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) |
215 | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF |
216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF |
219 | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose |
217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose |
218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose |
220 | HepB recombinant, 3-antigen, Al(OH)3 |
221 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose |
222 | Tick-borne encephalitis, unspecified |
223 | Tick-borne encephalitis, inactivated, PF, 0.25mL |
224 | Tick-borne encephalitis, inactivated, PF, 0.5mL |
225 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL |
226 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL |
512 | SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) |
513 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) |
514 | SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) |
515 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) |
516 | COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) |
517 | SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) |
227 | COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose |
228 | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose |
229 | COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose |
301 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose |
300 | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose |
230 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL |
518 | COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) |
519 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna |
520 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech |
521 | COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK |
231 | influenza, Southern Hemisphere, high-dose, quadrivalent |
303 | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF |
304 | Respiratory syncytial virus (RSV), unspecified |
305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF |
306 | RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months |
307 | RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months |
313 | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL |
308 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL |
309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL |
310 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL |
312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL |
311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL |
315 | Respiratory syncytial virus (RSV) MAB, unspecified |
314 | Respiratory syncytial virus (RSV) vaccine, unspecified |
316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF |
317 | Chikungunya live attenuated vaccine, 0.5 mL, PF |
318 | Anthrax, post-exposure prophylaxis |
319 | Anthrax vaccine, unspecified |
320 | Influenza, MDCK, trivalent, preservative |
321 | Influenza-avian, H5N8, monovalent, PF |
322 | Influenza-avian, H5N8, monovalent, preservative |
324 | Poliovirus, inactivated, fractional-dose (fIPV) |
323 | Influenza-avian, H5, unspecified formulation |
326 | RSV, mRNA, injectable, PF |
327 | Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF |
328 | Meningococcal oligosaccharide (MenACWY), (MenB), PF |
329 | Chikungunya, VLP, recombinant, 0.8 mL, PF |
330 | Dengue fever, unspecified |
331 | Influenza, Southern Hemisphere, trivalent, PF |
325 | Vaccinia (smallpox, mpox), unspecified |
332 | RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PF |
333 | Influenza, live, trivalent, intranasal, self/caregiver admin, PF |
302 | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose |
Expansion from tx.fhir.org based on codesystem Vaccine Administered Code Set (CVX) version20250715
This value set contains 278 concepts
Explanation of the columns that may appear on this page:
Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
Code | The code (used as the code in the resource instance) |
Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
Definition | An explanation of the meaning of the concept |
Comments | Additional notes about how to use the code |